SGLT2 inhibitors

DRUG9 trials

Sponsors

Kitasato University School of Medicine,Endocrinology and Metabolism., Medical Corporation KYOSOKAI AMC Nishi Umeda Clinic, Khoo Teck Puat Hospital, Pharmaceuticals and Medical Devices Agency, Japan, Kurume University

Conditions

Adult Congenital Heart DiseaseCongenital Heart DiseaseCongenitally Corrected Transposition of the Great ArteriesDiabetes Mellitus, Type 2Effects of the DPP-4 Inhibitors or SGLT2 Inhibitors on the Protective Actions for Diabetic ComplicationsFontanPolycystic Ovary SyndromeSingle Ventricle

Phase 4

Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment

CompletedNCT02041234

Khoo Teck Puat HospitalType II Diabetes in Subjects BMI 27 to 32

Start: 2014-02-28End: 2022-06-30Target: 40Updated: 2022-06-23

Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors

Kurume UniversityEffects of the DPP-4 Inhibitors or SGLT2 Inhibitors on the Protective Actions for Diabetic Complications

Start: 2015-08-31End: 2018-08-31Target: 100Updated: 2015-08-19

SGLT2 Inhibitors in Patients With PCOS

CompletedNCT04700839

Shanghai 10th People's HospitalPolycystic Ovary Syndrome

Start: 2020-05-01End: 2021-04-30Updated: 2022-09-10

Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh

Not yet recruitingNCT06449235

Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic DisordersType2diabetes

Start: 2024-09-30End: 2025-06-30Target: 938Updated: 2024-07-16

Unknown Phase

Investigation of metabolic change by SGLT2 inhibitors in type 2 diabetes patients.

Active, not recruitingJPRN-UMIN000015057

Kitasato University School of Medicine,Endocrinology and Metabolism.type 2 diabetes

Start: 2014-08-19Target: 20Updated: 2025-07-18

Meta-analysis in Post-marketing Surveillances for SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus

Pharmaceuticals and Medical Devices Agency, JapanDiabetes Mellitus, Type 2

Start: 2014-10-31Target: 18000Updated: 2016-04-04

Study to evaluate release of glucose toxicity associated with SGLT2 inhibitors administered in patients with metabolic syndrome in type 2 diabetes

Active, not recruitingJPRN-UMIN000019660

Medical Corporation KYOSOKAI AMC Nishi Umeda ClinicType 2 diabetes

Start: 2015-11-01Target: 30Updated: 2025-07-18

SGLT2 Inhibitors in Treating Patients With PCOS

Enrolling by invitationNCT05966792

Shanghai 10th People's HospitalPolycystic Ovary Syndrome

Start: 2023-11-10End: 2025-06-30Target: 80Updated: 2025-06-11

Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry

RecruitingNCT06932081

Leiden University Medical CenterAdult Congenital Heart Disease, Congenital Heart Disease, Congenitally Corrected Transposition of the Great Arteries +5

Start: 2023-01-01End: 2027-12-31Target: 400Updated: 2026-02-13

Related Papers

Circulating Profiles of the Bile Acid Metabolomics in Patients With Polycystic Ovary Syndrome Treated With Metformin or Canagliflozin.

2025-12-16

Roux-en-Y gastric bypass versus best medical treatment for type 2 diabetes mellitus in adults with body mass index between 27 and 32 kg/m<sup>2</sup>: A 5-year randomized controlled trial.

2022-05-0216 citations